Correlation of p53 oncoprotein expression with chemotherapy response in small cell lung carcinomas

Lung Cancer

Volumn 34, Issue 1, 2001, Pages 67-74

  Rodríguez Salas, Nuria ^a   Palacios, José ^a   Moreno, Gema ^a   De Castro, Javier ^a   González Barón, Manuel ^a   Gamallo, Carlos ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Chemotherapy; Immunohistochemistry; P53; Prognostic factor; Small cell lung cancer

Indexed keywords

ANTIINFECTIVE AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; ONCOPROTEIN; PROTEIN P53; VINCRISTINE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034847546     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00230-6     Document Type: Article

References (42)

1. p53, cell cycle control and apoptosis: Implications for cancer
2. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
3. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas
4. Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma
5. p53: A frequent target for genetic abnormalities in lung cancer
6. Increased expression of mutant forms of p53 oncogene in primary lung cancer
7. High frequency of somatically acquired p53 mutations in small cell lung cancer cell lines and tumors
8. Histopathologic classification of small cell lung cancer
9. Survival in operable non-small-cell lung cancer: The role of p53 mutations, tobacco smoking and asbestos exposure
10. The meaning and use of the area under a receiver operating characteristic (ROC) curve
11. Cancer statistics, 1996
12. The fifty-year decline of cancer in America
13. Small cell lung cancer: Etiology, biology, clinical features, staging and treatment
14. Future directions in the therapeutic approaches for small cell lung cancer
15. Overview of chemotherapy for small cell lung cancer
16. Current management of small cell lung cancer
17. p53: The guardian of the genome
18. WAF-1, a potential mediator of p53 tumor suppression
19. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation
20. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer
21. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents
22. DNA damage, p53 and anticancer therapies
23. Induction chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild type p53 gene
24. Clinical significance of p53 in non-small-cell lung cancer
25. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer
26. Adenovirus-mediated p53 gene-transfer in sequences with cisplatin to tumors of patients with non-small-cell lung cancer
27. Immunohistochemical expression in breast carcinoma may predict therapeutic response to adjuvant treatment
28. Specific p53 mutations are associated with the novo resistance to doxorrubicin in breast cancer patients
29. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents
30. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer
31. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC
32. p53 and treatment of bladder cancer
33. Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: Possible role of p53
34. Immunohistochemical p53 protein status in non-small-cell lung cancer is a promising indicator in determining in vitro chemosensitivity to some anticancer drugs
35. Prognostic significance of p53 mutations in non-small cell lung cancer: A meta-analysis of 829 cases from eight published studies
36. P53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients
37. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer
38. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy
39. Tumor-suppressor p53: Implication for tumor development and prognosis
40. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate
41. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil and prednisone for breast cancer
42. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung